WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H319580
CAS#: 1632006-28-0
Description: Esaxerenone, also known as CS-3150, XL-550, is a nonsteroidal antimineralocorticoid which was discovered by Exelixis and is now under development by Daiichi Sankyo Company for the treatment of hypertension, essential hypertension, hyperaldosteronism, and diabetic nephropathies. It acts as a highly selective silent antagonist of the mineralocorticoid receptor (MR), the receptor for aldosterone, with greater than 1,000-fold selectivity for this receptor over other steroid hormone receptors, and 4-fold and 76-fold higher affinity for the MR relative to the existing antimineralocorticoids spironolactone and eplerenone.
Hodoodo Cat#: H319580
Name: Esaxerenone
CAS#: 1632006-28-0
Chemical Formula: C22H21F3N2O4S
Exact Mass: 466.12
Molecular Weight: 466.475
Elemental Analysis: C, 56.65; H, 4.54; F, 12.22; N, 6.01; O, 13.72; S, 6.87
Related CAS #: 1632006-28-0 880780-76-7 1072195-82-4 (+ isomer) 1072195-83-5 (- isomer)
Synonym: Esaxerenone; CS-3150; CS 3150; CS3150; XL-550; XL550; XL 550.
IUPAC/Chemical Name: 1-(2-hydroxyethyl)-4-methyl-N-(4-(methylsulfonyl)phenyl)-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carboxamide
InChi Key: NOSNHVJANRODGR-UHFFFAOYSA-N
InChi Code: InChI=1S/C22H21F3N2O4S/c1-14-18(21(29)26-15-7-9-16(10-8-15)32(2,30)31)13-27(11-12-28)20(14)17-5-3-4-6-19(17)22(23,24)25/h3-10,13,28H,11-12H2,1-2H3,(H,26,29)
SMILES Code: CS(C1=CC=C(NC(C2=CN(CCO)C(C3=CC=CC=C3C(F)(F)F)=C2C)=O)C=C1)(=O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info: CAS# 880780-76-7; 1072195-82-4 (+ isomer); 1072195-83-5 (- isomer); 1632006-28-0 (5S isomer)
| Biological target: | Esaxerenone (CS-3150) is a highly potent and selective non-steroidal mineralocorticoid receptor antagonist. |
| In vitro activity: | For example, as the rectangular voltage step from −80 to −10 mV with a duration of 40 ms was delivered (indicated in the inset of Figure 1A) to activate INa, the addition of 3 μM ESAX (esaxerenone) was noticed to result in an evident decrease in the peak or late amplitude of INa to 1104 ± 197 or 9 ± 1 pA (n = 8, p < 0.05) from control values of 1498 ± 241 or 19 ± 3 pA (n = 8), respectively. After removal of ESAX, the peak or late amplitude of the current returned to 1452 ± 228 or 18 ± 3 pA (n = 8, p < 0.05), respectively. Reference: Biomedicines. 2021 May; 9(5): 549. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8153305/ |
| In vivo activity: | All HSD-fed DSS rats died by 24 weeks of age (18 weeks of HSD feeding), whereas 100% of the LSD-fed DSS rats were alive even at 28 weeks, suggesting that the HSD-fed rats exhibited a relatively shorter lifespan (Figure 1A). However, 20% of the HSD-fed rats with concomitant intervention of esaxerenone were alive at 28 weeks. Kaplan-Meier curve analysis of the cumulative probability of survival revealed that esaxerenone treatment significantly improved mean survival time in the HSD-fed DSS rats. Reference: Int J Mol Sci. 2021 Feb; 22(4): 2069. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7922950/ |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 100.0 | 214.37 |
The following data is based on the product molecular weight 466.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | 1. Chang WT, Wu SN. Characterization of Direct Perturbations on Voltage-Gated Sodium Current by Esaxerenone, a Nonsteroidal Mineralocorticoid Receptor Blocker. Biomedicines. 2021 May 13;9(5):549. doi: 10.3390/biomedicines9050549. PMID: 34068333; PMCID: PMC8153305. 2. Rahman A, Sawano T, Sen A, Hossain A, Jahan N, Kobara H, Masaki T, Kosaka S, Kitada K, Nakano D, Imamura T, Ohsaki H, Nishiyama A. Cardioprotective Effects of a Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, in Dahl Salt-Sensitive Hypertensive Rats. Int J Mol Sci. 2021 Feb 19;22(4):2069. doi: 10.3390/ijms22042069. PMID: 33669786; PMCID: PMC7922950. 3. Bhuiyan AS, Rafiq K, Kobara H, Masaki T, Nakano D, Nishiyama A. Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice. Hypertens Res. 2019 Jun;42(6):892-902. doi: 10.1038/s41440-019-0211-0. Epub 2019 Jan 21. PMID: 30664703. |
| In vitro protocol: | 1. Chang WT, Wu SN. Characterization of Direct Perturbations on Voltage-Gated Sodium Current by Esaxerenone, a Nonsteroidal Mineralocorticoid Receptor Blocker. Biomedicines. 2021 May 13;9(5):549. doi: 10.3390/biomedicines9050549. PMID: 34068333; PMCID: PMC8153305. |
| In vivo protocol: | 1. Rahman A, Sawano T, Sen A, Hossain A, Jahan N, Kobara H, Masaki T, Kosaka S, Kitada K, Nakano D, Imamura T, Ohsaki H, Nishiyama A. Cardioprotective Effects of a Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, in Dahl Salt-Sensitive Hypertensive Rats. Int J Mol Sci. 2021 Feb 19;22(4):2069. doi: 10.3390/ijms22042069. PMID: 33669786; PMCID: PMC7922950. 2. Bhuiyan AS, Rafiq K, Kobara H, Masaki T, Nakano D, Nishiyama A. Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice. Hypertens Res. 2019 Jun;42(6):892-902. doi: 10.1038/s41440-019-0211-0. Epub 2019 Jan 21. PMID: 30664703. |
